January 30, 2024
Our "Meet the Expert" series introduces you to our team of experts around the world. This "behind the curtain" view will help you get to know who we are on a professional and personal level, and highlight how our colleagues work together on our higher purpose to improve patient health and safety throughout the complete product lifecycle.
Demis N. Lipe will be speaking at the 2024 Oncologic Emergency Medicine Conference held at the MD Anderson Cancer Center in Houston, TX. She will be discussing the latest updates on immunotherapy and CAR-T therapy. For more information, visit the 2024 Oncologic Emergency Medicine Conference and the LinkedIn Event page.
I enjoy working with clients because it allows me to apply my medical expertise collaboratively. I find satisfaction in understanding their specific requirements, tailoring our approach to meet their objectives, and providing valuable insights. Building strong relationships with clients enhances the overall project success and allows me to contribute meaningfully to their goals through effective communication and strategic support.
In my role at ProPharma as a Senior Medical Director, I provide functional oversight to medical monitors, support business development in various aspects such as proposal development, and collaborate on projects that directly impact patient outcomes. By overseeing medical monitoring activities, I contribute to the early detection of potential issues, ensuring that patient safety is prioritized throughout the drug development process. Additionally, my involvement in proposal development allows me to provide meaningful feedback on studies and interventions that are not only scientifically sound but also to give meaningful feedback on studies and interventions that are scientifically sound and prioritize patient well-being. Ultimately, my role revolves around aligning our efforts with the highest standards of medical practices, thereby supporting and improving the health and safety of patients in every aspect of our work at ProPharma.
I've learned that fostering open communication channels and embracing transparency are pivotal lessons in our industry. Clients entrust us with the responsibility of running their studies, and what I've found to be most valued is our commitment to clear and honest collaboration. By prioritizing transparent communication, we also build trust and ensure that our clients are well-informed every step of the way. This dedication to openness defines our approach at ProPharma setting the foundation for successful partnerships and contributing to the advancement of patient-centric and impactful clinical research. Another lesson I have learned is the value of being nimble and solution-oriented. Clients appreciate our ability to navigate challenges swiftly, offering tailored solutions that keep their studies on track. In a dynamic environment, adaptability is not just an asset; it's a commitment to ensuring success.
As a Senior Medical Director at ProPharma, each day unfolds as a dynamic blend of responsibilities, reflecting the multifaceted nature of our growing organization. My role is comprehensive, from providing strategic oversight to hands-on involvement in medical monitoring, study management, safety assessments, client strategy or early engagement meetings, and beyond. I wear many hats to ensure our studies' success and the department's continuous growth. Whether it's guiding the team with strategic insights or diving into the intricacies of day-to-day operations, I am dedicated to doing whatever it takes to foster excellence and contribute to the success of our studies and the overall advancement of our department. Every day brings new challenges, and I embrace them with enthusiasm and commitment.
ProPharma redefines the traditional CRO model by offering tailored solutions prioritizing the client’s success. Our agile and flexible approach is what makes us different. It ensures that we adapt to the client’s unique needs, reducing delays and driving consistency throughout the project's life. We place clients at the center to maximize the probability of success.
September 19, 2018
On Thursday, September 13th, FDA published a proposed rule which would amend the current premarket submission requirements for medical devices. Background In July 2012, the Food and Drug...
August 15, 2022
Commercializing your medical device in the US market often requires submitting a marketing application to the FDA to become an FDA Approved or Cleared Medical Device. The content of your FDA...
June 22, 2021
The threat of cyber-attacks against medical devices is real. Medical devices capable of connecting, wirelessly, wired, or to portable media such as a USB drive, are more vulnerable to cybersecurity...